Lpl Technologies Engaged In Ovarian Cancer Detection

In the field of medical science, LPL Technologies, a cancer diagnostic company in Cleveland, New York, has become the sine qua non for gynecological cancer detection. The diagnosis initiated by the company includes a simple blood test for cancer detection. The test reveals the current condition of the patient. This test is again effective to detect breast cancer, as a particular combination of lipid is marked responsible for it

Ovarian cancer is the most fatal of the gynecological cancers and cannot be cured if not detected earlier. But the problem was that CA-125, the only test for the detection had not been approved by the Food and Drug Administration (FDA) as proper diagnosis. Cancer detection by CA-125 test often brought false results. The LPA (Lysophosphatidic acids) test of LPL Technologies is still waiting for FDA approval though it is reported that this is a more effective test to detect the cancer at earlier stage than the CA-125.

A report confirms that most of the cancer patients prefer LPA test to CA-125. LPA test is the detection of bioactive lipids (phospholipids), some fat-soluble molecules function of which is to be the messenger between the cells. LPL Technologies has detected LPA, one of those lipid molecules as responsible for ovarian or breast cancer. In 1998, a cancer center of Florida reported that LPA could be an indicator of the first-stage ovarian cancer. This is a very advanced test for cancer-detection among women.

A demonstration of the utility of LPA test as the prime detector of ovarian cancer was organized by LPL Technologies. The clinical trial of LPA satisfies the conditions for FDA approval. An independent study on 165 women shows that the test is 99% specific. The company along with some other private companies is trying to grab the market to sell an ovarian cancer test. In order to execute the plan the company is getting engaged in convincing women and Insurance Companies for the benefit of the test.

But there is a severe problem with the test. The 1% mistake is still counted as a serious matter for those unlucky 25 women of every 2500. They have to go through an abdominal surgery just to get the confirmation that they have cancer or not. It would be dangerous for some of them who would know after the painful surgery that they had no cancer.

This limitation of the diagnosis of LPL Technologies cannot be ignored. Now -a -days medical scientists have found an alternative. Proteomics, the study of proteins in the cells, tissues and body fluids, is another advanced test for cancer detection. LPA can be considered as the biomarker for ovarian cancer if the scientists can overcome the hindrance. The effectiveness of the test can be validated only by more and more researches before large-scale use.Frantzgroup